- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00183443
Treatment of Mania Symptoms With Drug Therapy
Divalproex Extended Release and Placebo, Lithium, or Quetiapine for Mania
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mania is a serious condition characterized by extreme excitement, mental and physical hyperactivity, insomnia, and disconnected thoughts. Symptoms of mania are common in patients with schizophrenia or bipolar disorder. When associated with these conditions, mania reaches psychotic proportions and often includes hallucinations, paranoia, and feelings of omnipotence. Such symptoms may put individuals with mania and those around them at risk for physical harm. Drug therapies that can safely and effectively treat symptoms of mania are needed. This study will compare three drug combinations in their ability to treat symptoms of mania in people with schizophrenia or bipolar I disorder.
This study will comprise a 12-week acute phase and a 14-week continuation phase. While the acute phase is the primary component of this study, the continuation phase will provide extended data on the characteristics and course of responders to the initial treatment combinations. Results from the continuation phase will be reported elsewhere. In the acute phase, participants will be randomly assigned to receive one of three treatments: divalproex-extended release (DV-ER) and lithium, DV-ER and quetiapine, or DV-ER and placebo. Participants will receive their intervention for 12 weeks. Participants will have weekly study visits for the first 4 weeks of the acute phase; biweekly study visits will occur for the following 8 weeks. After the acute phase, participants who have not responded to their drug regimen will complete their participation in the study.
Participants whose symptoms of mania have decreased will be offered enrollment in the 14-week continuation phase, during which time participants will continue the drug regimen they began in the acute phase. Participants will have biweekly study visits in the continuation phase. During each study visit in both phases, participants will be interviewed about their mania symptoms. Mania, depression, quality of life, and overall functioning scales will assess participants at study entry, at the end of the acute phase, and at the end of the continuation phase. Participants over 50 years of age will have an electrocardiogram (EKG) at study entry to determine cardiac function.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- VA Palo Alto Health Care System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of bipolar I disorder or schizophrenia
- Experiencing symptoms of mania at study entry
- Able to speak and understand English
- Willing and able to comply with all study requirements
Exclusion Criteria:
- History of partial response or nonresponse to any of the drugs or drug combinations given in this study
- History of intolerance to DVP, DVP-ER, lithium, or quetiapine
- Disorders that would contraindicate the use of DV, DV-ER, lithium, or quetiapine
- Use of antidepressants within 1 month prior to study entry
- Use of fluoxetine within 3 months prior to study entry
- Impaired cardiac function, as evidenced by abnormal EKG in participants 50 or over
- Unstable medical illness within 2 months prior to study entry
- At risk for suicide
- Substance abuse or dependence within 1 month prior to study entry
- Pregnancy, breastfeeding, or plans to become pregnant during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: DVP + placebo
Participants will receive divalproex ER at a therapeutic dose, plus placebo
|
Divalproex ER will be given in 250 mg or 500 mg tablets.
Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
Other Names:
|
Active Comparator: DVP + Quetiapine
Participants will receive divalproex ER at a therapeutic dose, plus quetiapine up to 800 mg
|
Divalproex ER will be given in 250 mg or 500 mg tablets.
Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
Other Names:
Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
Other Names:
|
Active Comparator: DVP + Lithium
Participants will receive divalproex ER at a therapeutic dose, plus lithium at a therapeutic blood level
|
Divalproex ER will be given in 250 mg or 500 mg tablets.
Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
Other Names:
Extended release lithium will be provided in 300 mg capsules.
Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptoms of Mania, as Measured by Young Mania Rating Scale
Time Frame: Week 12
|
Symptoms of mania, as measured by Young Mania Rating Scale.
The scale is eleven-item multiple choice diagnostic questionnaire (range 0-60), which psychiatrists use to measure the severity of manic episodes in children and young adults.
Typically, 20 is the minimum score required for mania.
Higher scores represent increased severity of mania symptoms.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Rating Scale for Depression (HAM-D,17)
Time Frame: Week 12
|
The Hamilton Rating Scale for Depression is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
The questionnaire is designed for adults and is used to rate the severity of their depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms.
The 17-item Likert-type scale (range 0-50) includes eight questions with a 5-point scale (ranging from 0=not present to 4=severe) and nine items scored from 0 to 2. Higher scores indicate increased depression severity.
The total sum of these 17 answers is used to arrive at the final score: normal (0-7), mild (8-13), moderate (14-18), severe (19-22), or very severe (>=23).
|
Week 12
|
Clinical Global Impression Scale for Bipolar Disorder (CGI-BD)
Time Frame: Week 12
|
The Clinical Global Impression (CGI) rating scale was modified by Spearing and colleagues (1997) for use in bipolar disorder.
CGI scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders.
The revised CGI-Bipolar Version (CGI-BP) is effective in rating severity of manic and depressive episodes and the degree of change from the immediately preceding phase and from the worst phase of illness.
The CGI-BP is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal, not ill) to 7 (very severely ill).
Each component of the CGI is rated separately; the instrument does not yield a global score.
Only severity of illness scores are reported.
Increased scores represent increased illness severity
|
Week 12
|
Global Assessment of Functioning
Time Frame: Week 12
|
The Global Assessment of Functioning (GAF) is a numeric scale used by mental health clinicians and physicians to rate subjectively the social, occupational, and psychological functioning of an individual, e.g., how well one is meeting various problems-in-living.
Scores range from 100 (extremely high functioning) to 1 (severely impaired).
|
Week 12
|
Social and Occupational Functioning Assessment Scale (SOFAS)
Time Frame: Week 12
|
The Social and Occupational Functioning Assessment Scale (SOFAS) provides a rating of global social and occupational function independent of clinical symptoms.
SOFAS is provided in the Diagnostic and Statistical Manual (DSM-IV) as an Axis V measure.
The SOFAS is a global rating of current functioning, which is scored positively on a scale from 0 to 100.
Higher scores represent higher levels of functioning.
This instrument is a one-item rating of consumer functioning.
|
Week 12
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Trisha Suppes, MD, PhD, Stanford School of Medicine and VA Palo Alto Health Care System
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Bipolar and Related Disorders
- Schizophrenia
- Bipolar Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Valproic Acid
- Quetiapine Fumarate
Other Study ID Numbers
- SUP0001AGG/ADO
- DSIR 83-ATSO (National Institute of Mental Health)
- R01MH069801 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Divalproex-extended release (DVP-ER)
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy (HIBM)United States
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy | GNE MyopathyUnited States, Israel
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka TypeUnited States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
-
TaiRx, Inc.CompletedAdvanced CancerTaiwan
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyCanada, United States, Bulgaria
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyUnited States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
-
Zogenix, Inc.Completed
-
Vince & Associates Clinical Research, Inc.Food and Drug Administration (FDA)Unknown
-
Janssen Research & Development, LLCCompleted